Board of Directors
Remi Gaston-Dreyfus — Director
Mr. Gaston-Dreyfus has been a Director of the Company since September 1, 2017. Mr. Gaston-Dreyfus has also served as a board member of Christie’s in Paris since 2014. Mr. Gaston-Dreyfus has been the CEO and Founder of GDG Investissements S.A.S in Paris, a developer and investor in real estate assets in Paris, since 2007. Prior to 2007, Mr. Gaston-Dreyfus was a shareholder, Chairman and CEO of the Photo-journalism group A.G.I. (including Gamma Press Agency). Mr. Gaston-Dreyfus was a co-founder of a Parisian law firm in 1984, and was a lawyer in France until 1992.
Michal Prywata — Director
Mr. Prywata is the co-founder and Chief Technology Officer of BIONIK Laboratories. He studied biomedical engineering at Ryerson University and has a proven track record of inventing and winning technology showcases. While attending Ryerson, Mr. Prywata co-invented the world’s first robotic, prosthetic arm that is controlled by brain signals. Equally impressive is his strong understanding of developing technologies that address significant and untapped markets. He is responsible for raising the initial capital to found Bionik and turn numerous concepts into products.
Richard Russo, Jr., CPA — President and CEO
Richard Russo, Jr. has served as the Company’s Chief Financial Officer since November 2020 and the interim Chief Executive Officer since July 2021. He has over 15 years of finance and accounting leadership experience and holds a CPA.
From 2017-2020, Russo, Jr. served as Vice President of Finance and U.S. Chief Financial Officer of ICarbonX, where he was responsible for the merger of 3 companies, fundraising, and the ultimate dissolution of the U.S. companies.
From 2007-2016, Russo, Jr. held various key leadership roles for NASDAQ listed companies in life sciences, pharmaceutical and medical device industries. He served as Corporate Controller for: Pieris Pharmaceuticals, Inc., a clinical stage biotechnology company; Juniper Pharmaceuticals, a woman’s health company focused on developing therapeutics and; Cynosure a medical device company focused on aesthetic treatment systems. In each of these roles, Russo, Jr. was responsible for all finance activities and SEC reporting along including partnering closely with the business leaders to ensure effective and efficient financial procedures throughout the organization.
Russo, Jr. started his career in 2005, where he served as an auditor at Pricewaterhouse Coopers in the assurance group.
Request an InMotion Therapy Demo
